Stem Cell Educator Therapy in Type 2 Diabetes
Primary Purpose
Type 2 Diabetes
Status
Completed
Phase
Phase 1
Locations
China
Study Type
Interventional
Intervention
Stem Cell Educator
Sponsored by

About this trial
This is an interventional treatment trial for Type 2 Diabetes focused on measuring Cord blood stem cells, inflammation, type 2 diabetes, stem cell educator, autoimmunity, immune modulation
Eligibility Criteria
Inclusion Criteria:
- Patients were screened for enrollment in the study if both clinical signs and laboratory tests meet the diagnosis standards of American Diabetes Association 2010. Other key inclusion criteria were presence of at least one autoantibody to the pancreatic islet β cells for the autoimmune-related type 2 diabetes.
Exclusion Criteria:
- Exclusion criteria were any clinically significant diseases in liver, kidney, and heart. Additional exclusion criteria were no pregnancy, no immunosuppressive medication, no viral diseases or diseases associated with immunodeficiency.
Sites / Locations
- General Hospital of Jinan Military Command
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Experimental
Arm Label
Cord blood stem cell
Stem Cell Educator
Arm Description
Human cord blood-derived multipotent stem cells (CB-SC) display unique phenotypes, such as the expression of embryonic stem (ES) cell markers, multipotential of differentiations, very low immunogenecity, and immune modulations. Stem Cell Educator will be used for isolation and purification of cord blood stem cells for the treatment.
used for the isolation and purification of cord blood stem cells.
Outcomes
Primary Outcome Measures
Inflammation control
Before treatment, test inflammation-related markers as baseline; After treatment for 30 days, repeat testing inflammation-related markers.
Secondary Outcome Measures
Metabolic control
Before treatment, test for HbA1C levels as baseline; After treatment, test HbA1C levels on the 3rd month
Full Information
NCT ID
NCT01415726
First Posted
August 10, 2011
Last Updated
February 16, 2012
Sponsor
University of Illinois at Chicago
Collaborators
Chinese government, Jinan Tianhe Stem Cell Biotechnologies Co Ltd
1. Study Identification
Unique Protocol Identification Number
NCT01415726
Brief Title
Stem Cell Educator Therapy in Type 2 Diabetes
Study Type
Interventional
2. Study Status
Record Verification Date
July 2011
Overall Recruitment Status
Completed
Study Start Date
July 2011 (undefined)
Primary Completion Date
February 2012 (Actual)
Study Completion Date
February 2012 (Actual)
3. Sponsor/Collaborators
Name of the Sponsor
University of Illinois at Chicago
Collaborators
Chinese government, Jinan Tianhe Stem Cell Biotechnologies Co Ltd
4. Oversight
5. Study Description
Brief Summary
Type 2 diabetes is the most common form of diabetes. The prevalence of diabetes has been markedly increased in recent years. More and more children and young adults develop this devastating disease. Despite of multiple factors (e.g., food, environmental, and genetic factors) contributing to the developing of diabetes, increasing evidence demonstrated that chronic inflammation and/or atuoimmunity are common issues and play key roles in the pathogenesis of type 2 diabetes, leading to the insulin resistance and the shortage of insulin-producing islet beta cells. Thus, anti-inflammation is becoming a novel approach for the treatment of type 2 diabetes. Evidence that multipotent stem cells derived from human cord blood (CB-SCs) can control inflammation and autoimmune responses by altering regulatory T cells (Tregs) and human islet beta cell-specific T cell clone in type 1 diabetes offers promise for a new approach to treat type 2 diabetes. Here, the investigators develop a novel Stem Cell Educator therapy by using CB-SC and explore the therapeutic effectiveness of Stem Cell Educator therapy in T2D patients.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Type 2 Diabetes
Keywords
Cord blood stem cells, inflammation, type 2 diabetes, stem cell educator, autoimmunity, immune modulation
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 1, Phase 2
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
25 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Cord blood stem cell
Arm Type
Experimental
Arm Description
Human cord blood-derived multipotent stem cells (CB-SC) display unique phenotypes, such as the expression of embryonic stem (ES) cell markers, multipotential of differentiations, very low immunogenecity, and immune modulations. Stem Cell Educator will be used for isolation and purification of cord blood stem cells for the treatment.
Arm Title
Stem Cell Educator
Arm Type
Experimental
Arm Description
used for the isolation and purification of cord blood stem cells.
Intervention Type
Device
Intervention Name(s)
Stem Cell Educator
Intervention Description
For the treatment, commonly the left (or right) median cubital vein, a patient's blood is passed through a Blood Cell Separator that isolates the lymphocytes from the blood according to the recommended protocol by manufacture; consequently, the collected lymphocytes were transferred into the Stem Cell Educator and treated by CB-SC; after that, the educated cells return the blood back to the patient via a dorsal vein of hand. During the MCS+ collection, the whole blood flow rate was maintained at 35 mL/min. The whole procedure was scheduled for 6 ~ 7 hrs.
Primary Outcome Measure Information:
Title
Inflammation control
Description
Before treatment, test inflammation-related markers as baseline; After treatment for 30 days, repeat testing inflammation-related markers.
Time Frame
30 days post treatment
Secondary Outcome Measure Information:
Title
Metabolic control
Description
Before treatment, test for HbA1C levels as baseline; After treatment, test HbA1C levels on the 3rd month
Time Frame
3 months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
14 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
Patients were screened for enrollment in the study if both clinical signs and laboratory tests meet the diagnosis standards of American Diabetes Association 2010. Other key inclusion criteria were presence of at least one autoantibody to the pancreatic islet β cells for the autoimmune-related type 2 diabetes.
Exclusion Criteria:
Exclusion criteria were any clinically significant diseases in liver, kidney, and heart. Additional exclusion criteria were no pregnancy, no immunosuppressive medication, no viral diseases or diseases associated with immunodeficiency.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Yong Zhao, MD, PhD
Organizational Affiliation
Universtiy of Illinois at Chicago
Official's Role
Principal Investigator
Facility Information:
Facility Name
General Hospital of Jinan Military Command
City
Jinan
State/Province
Shandong
ZIP/Postal Code
250031
Country
China
12. IPD Sharing Statement
Citations:
PubMed Identifier
20728583
Citation
Zhao Y, Mazzone T. Human cord blood stem cells and the journey to a cure for type 1 diabetes. Autoimmun Rev. 2010 Dec;10(2):103-7. doi: 10.1016/j.autrev.2010.08.011. Epub 2010 Aug 20.
Results Reference
background
PubMed Identifier
20403575
Citation
Zhao Y, Lin B, Dingeldein M, Guo C, Hwang D, Holterman MJ. New type of human blood stem cell: a double-edged sword for the treatment of type 1 diabetes. Transl Res. 2010 May;155(5):211-6. doi: 10.1016/j.trsl.2010.01.003. Epub 2010 Feb 12.
Results Reference
background
PubMed Identifier
19156219
Citation
Zhao Y, Lin B, Darflinger R, Zhang Y, Holterman MJ, Skidgel RA. Human cord blood stem cell-modulated regulatory T lymphocytes reverse the autoimmune-caused type 1 diabetes in nonobese diabetic (NOD) mice. PLoS One. 2009;4(1):e4226. doi: 10.1371/journal.pone.0004226. Epub 2009 Jan 19.
Results Reference
background
PubMed Identifier
23837842
Citation
Zhao Y, Jiang Z, Zhao T, Ye M, Hu C, Zhou H, Yin Z, Chen Y, Zhang Y, Wang S, Shen J, Thaker H, Jain S, Li Y, Diao Y, Chen Y, Sun X, Fisk MB, Li H. Targeting insulin resistance in type 2 diabetes via immune modulation of cord blood-derived multipotent stem cells (CB-SCs) in stem cell educator therapy: phase I/II clinical trial. BMC Med. 2013 Jul 9;11:160. doi: 10.1186/1741-7015-11-160.
Results Reference
derived
Learn more about this trial
Stem Cell Educator Therapy in Type 2 Diabetes
We'll reach out to this number within 24 hrs